Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zura Bio Limited filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing antibody candidates for autoimmune and inflammatory diseases. Its disclosures include operating and financial results, Regulation FD materials, clinical-program communications, and risk-related context for a multi-asset immunology pipeline led by tibulizumab (ZB-106).
The company’s SEC record also covers proxy governance matters, annual general meeting voting, executive and compensation arrangements, and capital-structure activity involving Class A ordinary shares, pre-funded warrants, underwriting agreements, and related legal opinions. Current reports and proxy materials provide formal disclosure of material events, shareholder matters, and emerging growth company status.
Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and from the Board’s Nominating and Governance Committee effective December 11, 2025. The company states that his decision is not due to any disagreement with its operations, policies or practices.
The disclosure centers on this board-level governance change. Zura Bio is organized in the Cayman Islands, is an emerging growth company, and its Class A ordinary shares trade on the Nasdaq Stock Market under the symbol ZURA.
Zura Bio Limited reported its Q3 2025 results. Cash and cash equivalents were $139.0 million as of September 30, 2025, compared with $176.5 million at year-end 2024. The company recorded a net loss of $18.0 million for the quarter and $51.5 million for the nine months, reflecting ongoing investment in clinical programs.
Quarterly operating expenses were $19.5 million, with research and development at $11.9 million and general and administrative at $7.6 million. Net cash used in operating activities was $42.5 million for the nine months. Management states it should have sufficient liquidity to fund operations over the next twelve months.
The pipeline centers on Phase 2 development of tibulizumab (ZB-106), a dual IL‑17A/BAFF bispecific antibody. During 2025, the company sold 3,000,000 shares under its ATM at $1.75 for $5.1 million in net proceeds. Class A Ordinary Shares outstanding were 65,018,058 as of September 30, 2025, and 65,023,308 as of November 10, 2025.
Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.
Zura Bio Limited reported a leadership change triggered by a medical leave. On October 8, 2025, Chief Executive Officer and Board member Robert Lisicki informed the company that he is taking a medical leave of absence effective October 10, 2025.
The Board appointed Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as interim Chief Executive Officer and interim principal executive officer starting October 10, 2025, while she continues in her existing roles. The company notes that there are no special arrangements behind her appointment, no related-party transactions requiring disclosure, and no family relationships between Davis and any directors or executive officers.
Zura Bio Limited reported that its Board adopted an Executive Severance Benefit Plan covering certain employees, including current named executive officers. Under the plan, if an eligible executive is terminated without cause or resigns for good reason after at least 91 days of employment, the Chief Executive Officer may receive a lump sum equal to 12 months of base salary, while other named executive officers and certain executives may receive nine months of base salary.
If a qualifying termination occurs within 12 months after a change in control, the benefits increase. In that case, the Chief Executive Officer may receive 18 months of base salary, 150% of target annual bonus, a prorated bonus for the year of termination based on actual performance, and up to 18 months of COBRA or comparable health coverage reimbursement. Other named executive officers and certain executives may receive 12 months of base salary, 100% of target annual bonus, a prorated actual-performance bonus, and up to 12 months of COBRA or comparable coverage reimbursement.
Zura Bio Limited reported that it has prepared an updated corporate presentation as of September 4, 2025. The presentation may be used at conferences and investor meetings to explain the company’s business and outlook.
The updated deck is filed as Exhibit 99.1 and is also available in the News & Events section of Zura Bio’s investor website. The company notes that this material is being furnished under a disclosure item for investor information and is not considered filed for liability purposes under U.S. securities laws or automatically incorporated into other SEC filings.
Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025. The company states that the information in Item 7.01 and Exhibit 99.1 is being provided under Regulation FD and is considered “furnished,” not “filed,” which means it is not subject to certain liability provisions of the Exchange Act unless later specifically incorporated by reference. The filing identifies the press release as Exhibit 99.1 and also includes a cover page interactive data file as Exhibit 104.
Zura Bio Limited ownership disclosure: A group led by Venrock entities and two individuals reports beneficial ownership of 6,353,353 Class A Ordinary Shares, representing 9.99% of the class as of June 30, 2025. The position reflects direct Class A shares and pre-funded warrants exercisable into additional Class A shares, but those warrants include a Beneficial Ownership Blocker that prevents exercise that would push the group above the 9.99% threshold. The percentage is calculated using 61,874,998 outstanding Class A shares plus 1,722,137 shares issuable on warrant exercise. Voting and dispositive power are shown as shared for the 6,353,353 shares, with no sole voting or dispositive power reported.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report a collective stake of 4,616,514 Class A Ordinary Shares in ZURA Bio Ltd, representing 7.13% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power for all 4,616,514 shares and no sole voting or dispositive power. The ownership calculation uses a share base of 64,763,950, which combines 61,874,998 outstanding ordinary shares and 2,882,952 pre-funded warrants that the reporting persons could convert subject to a 9.99% maximum exercise limitation. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.
The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.